SavedAdd your journal

Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2020 / Cilt: 73 - Sayı: 1

Tofacitinib in Patients with Rheumatoid Arthritis: Single-center Experience Rheumatoid Arthritis and Tofacitinib

Romatoid Artritli Hastalarda Tofasitinib: Tek Merkez Deneyimi Romatoid Artirit ve Tofasitinib

Tahsin Murat TURGAY
Murat TORGUTALP
Gülay KINIKLI
Didem ŞAHİN
Serdar SEZER
Ayşe Bahar KELEŞOĞLU DİNÇER
Emine Gözde AYDEMİR GÜLOKSUZ
Mehmet Levent YÜKSEL
Aşkın ATEŞ
Müçteba Enes YAYLA
Pages
20–25
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Drug survival rates were analyzed using Kaplan-Meier survival analysis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to determine the clinical, laboratory and demographic characteristics of patients with rheumatoid arthritis (RA) using tofacitinib, and the drug survival rates.
📊
Key Findings & Data:Materials and Methods: A total of 78 RA patients who were prescribed tofacitinib between May 2016 and July 2019 were retrospectively evaluated and included in the study.
💡
Conclusion & Impact:Drug survival rates were analyzed using Kaplan-Meier survival analysis.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we aimed to determine the clinical, laboratory and demographic characteristics of patients with rheumatoid arthritis (RA) using tofacitinib, and the drug survival rates. Materials and Methods: A total of 78 RA patients who were prescribed tofacitinib between May 2016 and July 2019 were retrospectively evaluated and included in the study. The clinical, laboratory and demographic features of the patients were recorded. Drug survival rates were analyzed using Kaplan-Meier survival analysis. P

Özet

Amaç: Çalışmamızda romatoid artrit (RA) nedeni ile tofasitinib kullanan hastaların klinik, laboratuvar ve demografik özelliklerini belirlemek ve ilaçtakalım oranlarını saptamak amaçlanmıştır.Gereç ve Yöntem: Mayıs 2016-Temmuz 2019 tarihleri arasında tofasitinib reçete edilmiş 78 RA hastası retrospektif olarak incelenerek çalışmayadahil edildi. Hastaların klinik, laboratuvar ve demografik verileri kaydedildi. İlaçta kalım hızları Kaplan-Meier sağ kalım analizi kullanılarak incelendi.P

🔖

Cite This Article

TURGAY, T. M., TORGUTALP, M., KINIKLI, G., ŞAHİN, D., SEZER, S., DİNÇER, A. B. K., GÜLOKSUZ, E. G. A., YÜKSEL, M. L., ATEŞ, A., YAYLA, M. E. (2022). Tofacitinib in Patients with Rheumatoid Arthritis: Single-center Experience Rheumatoid Arthritis and Tofacitinib. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 73 - Sayı: 1, 20–25. https://ajindex.com/articles/443547

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32-40
  2. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960- 977
  3. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457-468
  4. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. Rheumatology (Oxford). 2016;55:1031-1041
  5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581. 6. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-1850
  6. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244-257
  7. Nurmohamed MT, Dijkmans BA. Are biologics more effective than classical disease-modifying antirheumatic drugs? Arthritis Res Ther. 2008;10:118
  8. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451-460
  9. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2013;159:253-261
  10. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507
  11. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837-852
  12. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib